Novel Galantamine-ferulicacid hybrids: A Multi-target approach to Alzheimer’s disease

Alzheimer's disease is a degenerative illness that can make it difficult for a person to communicate or react to their surroundings. The ageing process is a complex one that alters a person's ability to operate normally over time. This change is causing a decline in biological functioning, particularly those related to the brain and cognition. Memory and learning impairments are mostly caused by oxidative stress, amyloid-β buildup in the hippocampal area, and neuronal death. Thus, the aim of this research intended to evaluate the neuroprotective effects of Galantamine and/or Ferulic acid alone on rats that had Alzheimer's disease triggered by scopolamine. Followed a seven-day course of treatment with scopolamine at a dose of 1mg/kg (i.p.) to impair memory. Additionally, they were treated orally with 3mg/kg of Galantamine and 100mg/kg of Ferulic acid. It is divided into two groups: one for normal control (0.9% saline) and the other for disease control (scopolamine, 1mg/kg (i.p.) for 7 days), as well as standard groups scopolamine + Galantamine, 3mg/kg (po). The Test-1 group received scopolamine +Ferulic acid at a dose of 100mg/kg (po), while the Test-2 group received a combination of Galantamine and Ferulic acid for 21 days. At the start of the examination, all animals received physical exercise in addition to 28 days of treatment with galantamine, ferulic acid, and scopolamine. Every physical parameter was scheduled for testing on the 29th day. In comparison to the disease control group, the groups that received Galantamine and Ferulic acid (P< 0.0001) dramatically reduced the negative impact of scopolamine on the time it took to reach the favorable arm in the Y-maze. With daily treatment it shows the attenuated effect of scopolamine in rats by significantly reducing the AchE activity (p<0.0001) whereas increase in superoxide dismutase (p<0.0001). The present study confers that Galantamine with Ferulic acid possess neuroprotective effect in scopolamine induced AD in rats. It may be used as an alternative therapy strategy to treat Alzheimer's disease and improves the cognitive impairment by lowering oxidative stress.